Scilex Holding Co acquired Semnur, the SPAC

Scilex Holding Co -> Semnur, the SPAC · $2.5 Billion

• The proposed business combination would create a publicly traded biopharma company and further provide investment into Semnur for the development of a non-opioid product, SP-102 (10 mg injectable dexamethasone sodium phosphate viscous gel), or SEMDEXA ™ , a